Anika Therapeutics, Inc. (ANIK)
21.31
-0.47
(-2.16%)
USD |
NASDAQ |
Aug 24, 16:00
21.31
0.00 (0.00%)
After-Hours: 20:00
Anika Therapeutics Gross Profit Margin (Quarterly) : 65.15% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 65.15% |
| March 31, 2026 | 64.15% |
| December 31, 2025 | 62.65% |
| September 30, 2025 | 56.02% |
| June 30, 2025 | 50.90% |
| March 31, 2025 | 56.10% |
| December 31, 2024 | 55.96% |
| September 30, 2024 | 65.66% |
| June 30, 2024 | 66.69% |
| March 31, 2024 | 65.38% |
| December 31, 2023 | 68.51% |
| September 30, 2023 | 60.16% |
| June 30, 2023 | 65.40% |
| March 31, 2023 | 60.23% |
| December 31, 2022 | 60.90% |
| September 30, 2022 | 56.57% |
| June 30, 2022 | 62.69% |
| March 31, 2022 | 59.42% |
| December 31, 2021 | 50.62% |
| September 30, 2021 | 58.23% |
| June 30, 2021 | 54.56% |
| March 31, 2021 | 61.16% |
| December 31, 2020 | 51.23% |
| September 30, 2020 | 54.72% |
| June 30, 2020 | 44.79% |
| Date | Value |
|---|---|
| March 31, 2020 | 59.88% |
| December 31, 2019 | 70.95% |
| September 30, 2019 | 79.96% |
| June 30, 2019 | 77.53% |
| March 31, 2019 | 70.43% |
| December 31, 2018 | 74.03% |
| September 30, 2018 | 69.08% |
| June 30, 2018 | 73.31% |
| March 31, 2018 | 63.11% |
| December 31, 2017 | 70.34% |
| September 30, 2017 | 77.01% |
| June 30, 2017 | 81.13% |
| March 31, 2017 | 73.99% |
| December 31, 2016 | 73.76% |
| September 30, 2016 | 80.62% |
| June 30, 2016 | 77.18% |
| March 31, 2016 | 75.65% |
| December 31, 2015 | 79.64% |
| September 30, 2015 | 78.14% |
| June 30, 2015 | 76.97% |
| March 31, 2015 | 72.21% |
| December 31, 2014 | 76.30% |
| September 30, 2014 | 74.04% |
| June 30, 2014 | 79.70% |
| March 31, 2014 | 87.18% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | -1.31K% |
| MiMedx Group, Inc. | 68.50% |
| ABVC BioPharma, Inc. | -- |
| Enovis Corp. | 54.51% |
| Edwards Lifesciences Corp. | 78.09% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -2.20% |
| Return on Assets | -1.66% |
| Return on Invested Capital | -1.87% |
| Profit Margin (Quarterly) | 10.15% |
| Operating Margin (Quarterly) | 9.06% |
| Return on Net Operating Assets | -2.57% |